HSBC Analysts Give GlaxoSmithKline (LON:GSK) a GBX 2,110 Price Target

Share on StockTwits

GlaxoSmithKline (LON:GSK) has been assigned a GBX 2,110 ($27.57) price objective by investment analysts at HSBC in a report issued on Tuesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. HSBC’s price target would indicate a potential upside of 28.22% from the stock’s previous close.

A number of other equities analysts also recently weighed in on GSK. Citigroup reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, September 3rd. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, August 22nd. Goldman Sachs Group set a GBX 1,900 ($24.83) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Friday, August 23rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Finally, Kepler Capital Markets set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday, August 27th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 1,682.86 ($21.99).

LON GSK opened at GBX 1,645.60 ($21.50) on Tuesday. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,767 ($23.09). The company has a current ratio of 0.71, a quick ratio of 0.44 and a debt-to-equity ratio of 1,127.74. The company has a market capitalization of $82.69 billion and a PE ratio of 18.53. The firm’s fifty day simple moving average is GBX 1,681.02 and its 200-day simple moving average is GBX 1,591.26.

In other news, insider Vivienne Cox purchased 434 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was bought at an average cost of GBX 1,654 ($21.61) per share, for a total transaction of £7,178.36 ($9,379.80). Insiders have acquired 457 shares of company stock valued at $755,906 over the last 90 days.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More: Are sell-side analysts objective?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nanometrics  Lifted to Hold at BidaskClub
Nanometrics Lifted to Hold at BidaskClub
Nasdaq  Downgraded by BidaskClub
Nasdaq Downgraded by BidaskClub
NetScout Systems  Raised to “Hold” at BidaskClub
NetScout Systems Raised to “Hold” at BidaskClub
Intellia Therapeutics  Raised to Hold at BidaskClub
Intellia Therapeutics Raised to Hold at BidaskClub
Northern Trust  Lifted to “Hold” at BidaskClub
Northern Trust Lifted to “Hold” at BidaskClub
Liberty Latin America  Upgraded at BidaskClub
Liberty Latin America Upgraded at BidaskClub


© 2006-2019 Ticker Report